Comparative Pharmacology
Head-to-head clinical analysis: FENSOLVI KIT versus LUPRON DEPOT PED KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENSOLVI KIT versus LUPRON DEPOT PED KIT.
FENSOLVI KIT vs LUPRON DEPOT-PED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a GnRH agonist that initially stimulates and then suppresses pituitary gonadotropin release by downregulating GnRH receptors, leading to decreased testosterone and estradiol levels.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
45 mg subcutaneously every 6 months.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
None Documented
None Documented
3-4 hours (terminal); clinical suppression of LH/FSH persists 4 weeks post-injection.
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Primarily renal (~80%) and biliary/fecal (~20%) as metabolites and unchanged drug.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Category C
Category C
GnRH Agonist
GnRH Agonist